Published in Clin Sci Mol Med on October 01, 1974
Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J (1987) 2.20
Hyponatraemia: adverse effect of diuretic treatment. Br Med J (1977) 2.16
Effects of piretanide, bumetanide and frusemide on electrolyte and urate excretion in normal subjects. Br J Clin Pharmacol (1978) 1.82
Liquorice toxicity and the renin-angiotensin-aldosterone axis in man. Br Med J (1977) 1.56
Determinants of response to frusemide in normal subjects. Br J Clin Pharmacol (1977) 1.54
The mechanism of adaptation of left atrial stretch receptors in dogs with chronic congestive heart failure. J Clin Invest (1977) 1.10
Relation of plasma aldosterone concentration to diuretic treatment in patients with severe heart disease. Br Heart J (1979) 1.00
Hyponatraemia in congestive heart failure during treatment with captopril. Br Med J (1980) 0.96
Assessment of natriuretic drugs. Br J Clin Pharmacol (1981) 0.87
Drug treatment of heart failure. Br Heart J (1985) 0.84
Congestive heart failure in normotensive man. Haemodynamics, renin, and angiotensin II blockade. Br Heart J (1978) 0.83
Enalapril in African patients with congestive cardiac failure. Br J Clin Pharmacol (1989) 0.82
Enalapril in heart failure. Br J Clin Pharmacol (1984) 0.81
The effects of a combination of piretanide and triamterene in healthy subjects. Br J Clin Pharmacol (1981) 0.76
Diseases of the cardiovascular system. Cardiac failure. Br Med J (1976) 0.75
Effect of stilboestrol on sodium balance, cardiac state, and renin-angiotensin-aldosterone activity in prostatic carcinoma. Br Med J (Clin Res Ed) (1985) 0.75
Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease. Arch Dis Child (1981) 0.75
Sponsorship, authorship, and accountability. Lancet (2001) 7.10
Sponsorship, authorship, and accountability. N Engl J Med (2001) 6.20
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet (2000) 6.01
Sponsorship, authorship and accountability. CMAJ (2001) 5.86
Fluoride in drinking water and risk of hip fracture in the UK: a case-control study. Lancet (2000) 3.16
Unsatisfactory redefinition of myocardial infarction. Lancet (2001) 2.89
Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg Br (2005) 2.71
Management of raised blood pressure in New Zealand. N Z Med J (1993) 2.48
The Elag-Koln automatic blood pressure recorder. A clinical appraisal. Br Heart J (1977) 2.34
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation (1998) 2.17
Management of raised blood pressure. N Z Med J (1994) 2.03
Sjögren's syndrome and autoimmunity in a geriatric population. Age Ageing (1972) 2.01
Renal, haemodynamic, and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers. Lancet (1985) 1.95
Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) (1997) 1.73
Effect of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects. Br Med J (1977) 1.68
Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. Hum Mol Genet (2000) 1.61
Hypertension, lipoprotein(a), and apolipoprotein A-I as risk factors for stroke in the Chinese. Stroke (1991) 1.61
Effect of potassium-sparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure. Br Heart J (1976) 1.59
Liquorice toxicity and the renin-angiotensin-aldosterone axis in man. Br Med J (1977) 1.56
Effect of sulindac on angiotensin converting enzyme inhibitor-induced cough: randomised placebo-controlled double-blind cross-over study. J Hum Hypertens (1989) 1.55
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol (2001) 1.54
Cough with angiotensin converting-enzyme inhibitors. N Z Med J (1987) 1.48
Blood-pressure response to moderate sodium restriction and to potassium supplementation in mild essential hypertension. Lancet (1984) 1.48
Hypertension--still an important cause of heart failure? J Hum Hypertens (2005) 1.46
Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency. Clin Endocrinol (Oxf) (1996) 1.45
Biopterin-dependent hyperphenylalaninemia due to deficiency of 6-pyruvoyl tetrahydropterin synthase. Neurology (1991) 1.43
The management of mildly raised blood pressure in New Zealand: an alternative view. N Z Med J (1996) 1.42
Lithium associated thyroid disease--a report of 14 cases of hypothyroidism and 4 cases of thyrotoxicosis. Aust N Z J Med (1976) 1.42
A neural mechanism for sudden death after myocardial infarction. Clin Auton Res (2003) 1.41
Formaldehyde replaces glutaraldehyde in porcine bioprosthetic heart valves. J Heart Valve Dis (1996) 1.39
Recovery of S. epidermidis and E. coli from effluent peritoneal dialysate. Perit Dial Int (1991) 1.39
3-Hydroxybenzoate 6-hydroxylase from Pseudomonas aeruginosa. Biochem Biophys Res Commun (1973) 1.39
Sulindac and cough induced by converting enzyme inhibitors. Lancet (1987) 1.38
Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab (1993) 1.38
Calorie-restricted weight reduction, blood pressure, and atrial natriuretic peptides. Nutrition (1993) 1.38
Treatment of severe orthostatic hypotension with the somatostatin analogue octreotide. Aust N Z J Med (1990) 1.37
The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun (1995) 1.33
Adverse events and near miss reporting in the NHS. Qual Saf Health Care (2005) 1.31
Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab (1994) 1.29
High concentrations of thyroid-stimulating hormone in untreated glucocorticoid deficiency: indication of primary hypothyroidism? Br Med J (Clin Res Ed) (1982) 1.28
Haemodynamic, hormonal, and electrolyte responses to captopril in resistant heart failure. Lancet (1981) 1.26
Involvement of adenosine 3',5'-monophosphate in release of ACTH. Am J Physiol (1969) 1.26
Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies. Am J Cardiol (1982) 1.22
Sponsorship, authorship, and accountability. JAMA (2001) 1.22
Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab (1993) 1.21
Hyponatremic-hypertensive syndrome with renal ischemia: an underrecognized disorder. Hypertension (1999) 1.20
Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin H2 in the SHR aorta. Circ Res (1995) 1.20
Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J (1993) 1.19
Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease. Br Heart J (1985) 1.18
Biliary excretion of glutathione and glutathione disulfide in the rat. Regulation and response to oxidative stress. J Clin Invest (1984) 1.18
Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol (1985) 1.18
Importance of mild hyperoxaluria in the pathogenesis of urolithiasis--new evidence from studies in the Arabian peninsula. Scanning Microsc (1993) 1.17
Haemodynamic effects of atrial peptide infusion in heart failure. Lancet (1986) 1.16
Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ (1992) 1.15
Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab (1986) 1.14
Patients presenting with Addison's disease need not be pigmented. Postgrad Med J (1982) 1.13
Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab (2007) 1.13
An unusual cause of hyperinsulinaemic hypoglycaemia syndrome. Diabet Med (2003) 1.12
Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation (1999) 1.12
Natriuretic hormones. Endocrinol Metab Clin North Am (1995) 1.12
High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol (1995) 1.11
The haemodynamic, histopathological and hormonal features of alcoholic cardiac beriberi. Q J Med (1981) 1.10
A comparative study of some commercially available tests for rheumatoid factor. J Clin Pathol (1974) 1.09
Stroke subtypes among Chinese living in Hong Kong: the Shatin Stroke Registry. Neurology (1992) 1.09
Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clin Sci (Lond) (1980) 1.09
Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. Br Heart J (1983) 1.07
New government, same narrow vision. Health authorities in New Zealand have spin doctors to produce good news. BMJ (1998) 1.07
Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int (2000) 1.06
Multiple mechanisms are implicated in the generation of 5q35 microdeletions in Sotos syndrome. J Med Genet (2005) 1.06
Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci (1986) 1.06
Smith-Lemli-Opitz syndromes: do they include the Pallister-Hall syndrome? Am J Med Genet (1987) 1.05
The influence of hyperglycemia and diabetes mellitus on immediate and 3-month morbidity and mortality after acute stroke. Arch Neurol (1990) 1.05
Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure. Aust N Z J Med (1986) 1.05